PMC:7408073 / 100803-100961 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7408073","sourcedb":"PMC","sourceid":"7408073","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7408073","text":"300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597).","tracks":[{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":26,"end":34},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma85272"},{"subj":"T5","pred":"source","obj":"LitCovid-PD-FMA-UBERON"}]},{"project":"LitCovid-PD-CLO","denotations":[{"id":"T8","span":{"begin":8,"end":14},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T9","span":{"begin":48,"end":49},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"attributes":[{"subj":"T8","pred":"source","obj":"LitCovid-PD-CLO"},{"subj":"T9","pred":"source","obj":"LitCovid-PD-CLO"}]},{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T72202","span":{"begin":15,"end":19},"obj":"Chemical"}],"attributes":[{"id":"A87794","pred":"chebi_id","subj":"T72202","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"subj":"T72202","pred":"source","obj":"LitCovid-PD-CHEBI"}]},{"project":"LitCovid-sentences","denotations":[{"id":"T490","span":{"begin":0,"end":158},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T490","pred":"source","obj":"LitCovid-sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PD-FMA-UBERON","color":"#ecb193","default":true},{"id":"LitCovid-PD-CLO","color":"#9793ec"},{"id":"LitCovid-PD-CHEBI","color":"#a8ec93"},{"id":"LitCovid-sentences","color":"#ec93c2"}]}]}}